AbbVie Inc. (ABBV) Receives $93.21 Consensus Target Price from Brokerages

AbbVie Inc. (NYSE:ABBV) has received an average recommendation of “Buy” from the twenty ratings firms that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $93.15.

A number of research analysts have recently weighed in on ABBV shares. Jefferies Group LLC raised their price objective on shares of AbbVie from $107.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. BidaskClub raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 6th. Cowen and Company raised shares of AbbVie from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $91.17 to $105.00 in a research note on Wednesday, October 11th. BMO Capital Markets set a $66.00 price objective on shares of AbbVie and gave the stock a “hold” rating in a research note on Friday, October 27th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $100.00 price objective (up from $85.00) on shares of AbbVie in a research note on Friday, September 8th.

In related news, Chairman Richard A. Gonzalez sold 193,131 shares of AbbVie stock in a transaction on Monday, August 7th. The shares were sold at an average price of $71.00, for a total transaction of $13,712,301.00. Following the transaction, the chairman now owns 469,623 shares in the company, valued at approximately $33,343,233. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard A. Gonzalez sold 65,861 shares of AbbVie stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $71.00, for a total transaction of $4,676,131.00. Following the transaction, the chief executive officer now owns 342,353 shares in the company, valued at approximately $24,307,063. The disclosure for this sale can be found here. In the last quarter, insiders sold 380,190 shares of company stock worth $27,583,262. 0.23% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the stock. Bristlecone Advisors LLC acquired a new position in shares of AbbVie during the 3rd quarter valued at $113,000. Acropolis Investment Management LLC acquired a new position in shares of AbbVie during the 2nd quarter valued at $106,000. Ffcm LLC lifted its holdings in shares of AbbVie by 167.2% during the 2nd quarter. Ffcm LLC now owns 1,539 shares of the company’s stock valued at $111,000 after acquiring an additional 963 shares in the last quarter. Hudock Capital Group LLC lifted its holdings in shares of AbbVie by 109.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,542 shares of the company’s stock valued at $111,000 after acquiring an additional 806 shares in the last quarter. Finally, Hershey Trust Co. acquired a new position in shares of AbbVie during the 3rd quarter valued at $139,000. Institutional investors and hedge funds own 68.49% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/01/abbvie-inc-abbv-receives-93-21-consensus-target-price-from-brokerages.html.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a net margin of 24.38% and a return on equity of 164.66%. The business had revenue of $7 billion during the quarter, compared to analysts’ expectations of $7 billion. During the same period last year, the company posted $1.21 EPS. The company’s revenue was up 8.8% on a year-over-year basis.

The business also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Shareholders of record on Friday, January 12th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.15%. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio (DPR) is 62.29%.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply